Roberts, Glore & Co’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $550K | Sell |
3,001
-80
| -3% | -$14.7K | 0.15% | 122 |
|
|
2025
Q4 | $542K | Sell |
3,081
-848
| -22% | -$139K | 0.14% | 128 |
|
|
2025
Q3 | $550K | Sell |
3,929
-415
| -10% | -$56.1K | 0.15% | 125 |
|
|
2025
Q2 | $546K | Buy |
4,344
+181
| +4% | +$22.6K | 0.16% | 124 |
|
|
2025
Q1 | $570K | Buy |
4,163
+627
| +18% | +$89.6K | 0.17% | 119 |
|
|
2024
Q4 | $541K | Sell |
3,536
-148
| -4% | -$25K | 0.16% | 117 |
|
|
2024
Q3 | $714K | Buy |
3,684
+240
| +7% | +$50.2K | 0.21% | 103 |
|
|
2024
Q2 | $798K | Buy |
3,444
+89
| +3% | +$19.3K | 0.24% | 92 |
|
|
2024
Q1 | $723K | Buy |
3,355
+9
| +0.3% | +$2.11K | 0.22% | 99 |
|
|
2023
Q4 | $866K | Buy |
3,346
+4
| +0.1% | +$982 | 0.27% | 88 |
|
|
2023
Q3 | $859K | Sell |
3,342
-275
| -8% | -$73.6K | 0.28% | 85 |
|
|
2023
Q2 | $1.03M | Sell |
3,617
-217
| -6% | -$64.6K | 0.33% | 74 |
|
|
2023
Q1 | $1.07M | Sell |
3,834
-89
| -2% | -$24.6K | 0.36% | 73 |
|
|
2022
Q4 | $1.09M | Sell |
3,923
-1,703
| -30% | -$481K | 0.38% | 67 |
|
|
2022
Q3 | $1.5M | Sell |
5,626
-535
| -9% | -$114K | 0.54% | 52 |
|
|
2022
Q2 | $1.26M | Buy |
6,161
+813
| +15% | +$166K | 0.42% | 63 |
|
|
2022
Q1 | $1.13M | Buy |
5,348
+219
| +4% | +$47.6K | 0.32% | 73 |
|
|
2021
Q4 | $1.23M | Sell |
5,129
-890
| -15% | -$229K | 0.32% | 71 |
|
|
2021
Q3 | $1.7M | Sell |
6,019
-20
| -0.3% | -$6.55K | 0.52% | 53 |
|
|
2021
Q2 | $2.09M | Buy |
6,039
+108
| +2% | +$32.7K | 0.63% | 48 |
|
|
2021
Q1 | $1.66M | Buy |
5,931
+142
| +2% | +$38.3K | 0.52% | 53 |
|
|
2020
Q4 | $1.42M | Buy |
5,789
+248
| +4% | +$64K | 0.46% | 59 |
|
|
2020
Q3 | $1.57M | Buy |
5,541
+104
| +2% | +$29K | 0.56% | 51 |
|
|
2020
Q2 | $1.45M | Sell |
5,437
-24
| -0.4% | -$7.21K | 0.57% | 49 |
|
|
2020
Q1 | $1.73M | Buy |
5,461
+46
| +0.8% | +$14K | 0.74% | 39 |
|
|
2019
Q4 | $1.61M | Buy |
5,415
+2,464
| +83% | +$684K | 0.61% | 51 |
|
|
2019
Q3 | $687K | Buy |
2,951
+272
| +10% | +$63.3K | 0.42% | 69 |
|
|
2019
Q2 | $627K | Buy |
2,679
+180
| +7% | +$41.6K | 0.38% | 69 |
|
|
2019
Q1 | $591K | Sell |
2,499
-90
| -3% | -$28.3K | 0.37% | 73 |
|
|
2018
Q4 | $779K | Buy |
2,589
+7
| +0.3% | +$2.23K | 0.55% | 57 |
|
|
2018
Q3 | $912K | Hold |
2,582
| – | – | 0.52% | 54 |
|
|
2018
Q2 | $749K | Buy |
2,582
+105
| +4% | +$29.5K | 0.46% | 70 |
|
|
2018
Q1 | $678K | Buy |
2,477
+89
| +4% | +$27.6K | 0.42% | 71 |
|
|
2017
Q4 | $761K | Sell |
2,388
-110
| -4% | -$35.3K | 0.47% | 65 |
|
|
2017
Q3 | $782K | Buy |
2,498
+60
| +2% | +$17.8K | 0.51% | 65 |
|
|
2017
Q2 | $662K | Buy |
2,438
+70
| +3% | +$18.5K | 0.44% | 68 |
|
|
2017
Q1 | $647K | Buy |
2,368
+510
| +27% | +$144K | 0.45% | 69 |
|
|
2016
Q4 | $527K | Hold |
1,858
| – | – | 0.37% | 79 |
|
|
2016
Q3 | $582K | Hold |
1,858
| – | – | 0.42% | 71 |
|
|
2016
Q2 | $449K | Buy |
1,858
+510
| +38% | +$134K | 0.34% | 79 |
|
|
2016
Q1 | $351K | Buy |
1,348
+130
| +11% | +$34.3K | 0.27% | 93 |
|
|
2015
Q4 | $373K | Buy |
1,218
+98
| +9% | +$28.2K | 0.28% | 86 |
|
|
2015
Q3 | $327K | Sell |
1,120
-305
| -21% | -$101K | 0.26% | 96 |
|
|
2015
Q2 | $576K | Sell |
1,425
-150
| -10% | -$60.2K | 0.4% | 73 |
|
|
2015
Q1 | $665K | Sell |
1,575
-76
| -5% | -$30K | 0.46% | 64 |
|
|
2014
Q4 | $560K | Sell |
1,651
-54
| -3% | -$17.5K | 0.37% | 74 |
|
|
2014
Q3 | $564K | Sell |
1,705
-140
| -8% | -$46.2K | 0.39% | 72 |
|
|
2014
Q2 | $582K | Sell |
1,845
-75
| -4% | -$22.6K | 0.39% | 71 |
|
|
2014
Q1 | $587K | Sell |
1,920
-260
| -12% | -$82.5K | 0.41% | 72 |
|
|
2013
Q4 | $609K | Hold |
2,180
| – | – | 0.42% | 66 |
|
|
2013
Q3 | $525K | Sell |
2,180
-565
| -21% | -$126K | 0.39% | 72 |
|
|
2013
Q2 | $591K | Buy |
+2,745
| New | +$587K | 0.36% | 72 |
|
Other funds holding BIIB
VCM
VPM
Roberts, Glore & Co's BIIB Position: Q1 2026 in Review
Roberts, Glore & Co reduced its Biogen (BIIB) stake by 2.6% in Q1 2026, selling an estimated $14.7K and leaving 3,001 shares worth $550K. The position accounts for 0.15% of the portfolio, ranked #122.
Roberts, Glore & Co first reported a position in BIIB in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.09M in Q2 2021. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Roberts, Glore & Co held 3,001 shares of Biogen worth $550K as of Q1 2026.
- Roberts, Glore & Co sold 80 Biogen shares in Q1 2026, an estimated $14.7K.
- Biogen made up 0.15% of Roberts, Glore & Co's portfolio in Q1 2026, its #122 holding.
- Roberts, Glore & Co first reported a position in Biogen in Q2 2013 and has held it in 52 quarters since.
- Roberts, Glore & Co's Biogen position peaked at $2.09M in Q2 2021.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Roberts, Glore & Co's 13F filing for Q1 2026, filed 4 May 2026.